Protokinetix Inc (PKTX) 0.0907 $PKTX
ProtoKinetix Announces Share Issuance
Business Wire - Wed May 06, 3:53PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix"
(www.protokinetix.com) is pleased to announce that it has completed a private placement (the "Offering" for gross proceeds of $155,000. The Company has issued 1,937,500 shares of common stock at a price of $0.08 per share.
ProtoKinetix Accepts Director's Resignation
Business Wire - Fri May 01, 10:55AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" announces that it has received and accepted the resignation of Mr. Peter K. Jensen as a Director of the Company effective as of April 30, 2015. Mr. Jensen's resignation was due to personal reasons, and not as the result of any disagreement with the Company practices or policies.
ProtoKinetix Announces Acquisition of Patents
Business Wire - Mon Apr 27, 12:20PM CDT
ProtoKinetix, Incorporated (OTC
KTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" is pleased to announce that it has completed the acquisition of a portion of certain patents and all rights associated therewith (the "Patent Rights" pursuant to the Technology Transfer Agreement entered into with Grant Young on or about April 22, 2015. In exchange for the Patent Rights, Mr. Young will receive $10,000 in cash and a five-year warrant to purchase 6,000,000 shares of the Company's common stock at an exercise price of $0.10 per share.
ProtoKinetix enters into consulting agreements
M2 - Mon Apr 06, 6:02AM CDT
ProtoKinetix Incorporated (OTC: PKTX), a molecular biotechnology company, announced today the entering into consulting agreements with Clarence E. Smith, president and chief executive officer of the company, and Susan M. Woodward, chief financial officer of the company.
ProtoKinetix Announces Consulting Agreements
Business Wire - Fri Apr 03, 1:27PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix" (www.protokinetix.com) is pleased to announce that it has entered into consulting agreements with Clarence E. Smith, President and Chief Executive Officer of the Company, and Susan M. Woodward, Chief Financial Officer of the Company.
University of Alberta Diabetes Institute Encouraged by Preliminary Results of Testing of ProtoKinetix Licensed AAGP(TM) Molecule in Islet Cell Transplantation
Business Wire - Thu Mar 26, 3:00PM CDT
ProtoKinetix (OTC: PKTX) (www.protokinetix.com) is pleased to be able to report a comprehensive transplantation testing program being conducted for the last two years in conjunction with the University of Alberta transplant research team. The Company is collaborating with the James Shapiro Laboratory at the University of Alberta in Edmonton, Alberta. Dr. Shapiro directs the largest clinical islet transplantation program in the world.
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.16 (+0.22), NLSN: 45.57 (+0.53), VOYA: 44.81 (-0.14), NOC: 158.01 (+0.34), ARI: 17.41 (+0.12), OPHT: 52.02 (-0.56), WETF: 18.51 (-0.45), EVI: 4.28 (-0.01), MLNK: 3.57 (unch), DRRX: 2.35 (+0.01), RDUS: 46.23 (+1.12), AXDX: 23.08 (-0.05), HLX: 16.97 (+0.13), FANG: 78.93 (+1.73), FOXF: 16.48 (-0.20), SYK: 95.51 (+0.25), EHTH: 12.58 (-0.23)
ProtoKinetix Announces Settlement of Debt
Business Wire - Mon Mar 09, 9:23AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) today announced that it has retired its two largest debts to its largest creditor.
ProtoKinetix Inc. Announces Termination of Intrepid Agreement
Business Wire - Tue Oct 28, 9:23AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix" announces that it has terminated and revoked its agreement for the sale of exclusive rights to the AAGP(TM) Blood Preservative Applications (the "Agreement" to Intrepid Innovations Corporation ("Intrepid". The Company delivered a notice of termination and revocation to Intrepid on October 27, 2014, with revocation effective as of October 10, 2014, due to the failure by Intrepid to fulfill its payment obligations to ProtoKinetix under the Agreement.
ProtoKinetix Inc. Personnel Changes
Business Wire - Thu Oct 02, 9:54AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce that it has appointed Ms. Susan Woodward, as the Company's Chief Financial Officer. Ms. Woodward has over twenty-five years' experience in the accounting and management fields. She has held various positions throughout her career in a variety of industries including health care, the oil and gas industry and public accounting. Her experience includes cash and grant management, budget and financial preparation, data analysis, federal and state reporting, policy and procedure setting and oversight of all accounting functions.
ProtoKinetix Welcomes Clarence E. Smith to its Board of Directors
Business Wire - Fri Jun 20, 6:00AM CDT
ProtoKinetix (OTCBBKTX) (www.protokinetix.com) is pleased to announce the addition of entrepreneur and venture capitalist, Clarence E. Smith, to its Board of Directors. Mr. Smith brings much required, substantial financial and business experience with him as an addition to the Company's scientific accomplishments.
ProtoKinetix Announces Share Issuance
Business Wire - Wed May 06, 3:53PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix"
(www.protokinetix.com) is pleased to announce that it has completed a private placement (the "Offering" for gross proceeds of $155,000. The Company has issued 1,937,500 shares of common stock at a price of $0.08 per share. ProtoKinetix Accepts Director's Resignation
Business Wire - Fri May 01, 10:55AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company"
announces that it has received and accepted the resignation of Mr. Peter K. Jensen as a Director of the Company effective as of April 30, 2015. Mr. Jensen's resignation was due to personal reasons, and not as the result of any disagreement with the Company practices or policies. ProtoKinetix Announces Acquisition of Patents
Business Wire - Mon Apr 27, 12:20PM CDT
ProtoKinetix, Incorporated (OTC
KTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" is pleased to announce that it has completed the acquisition of a portion of certain patents and all rights associated therewith (the "Patent Rights" pursuant to the Technology Transfer Agreement entered into with Grant Young on or about April 22, 2015. In exchange for the Patent Rights, Mr. Young will receive $10,000 in cash and a five-year warrant to purchase 6,000,000 shares of the Company's common stock at an exercise price of $0.10 per share. ProtoKinetix enters into consulting agreements
M2 - Mon Apr 06, 6:02AM CDT
ProtoKinetix Incorporated (OTC: PKTX), a molecular biotechnology company, announced today the entering into consulting agreements with Clarence E. Smith, president and chief executive officer of the company, and Susan M. Woodward, chief financial officer of the company.
ProtoKinetix Announces Consulting Agreements
Business Wire - Fri Apr 03, 1:27PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix"
(www.protokinetix.com) is pleased to announce that it has entered into consulting agreements with Clarence E. Smith, President and Chief Executive Officer of the Company, and Susan M. Woodward, Chief Financial Officer of the Company. University of Alberta Diabetes Institute Encouraged by Preliminary Results of Testing of ProtoKinetix Licensed AAGP(TM) Molecule in Islet Cell Transplantation
Business Wire - Thu Mar 26, 3:00PM CDT
ProtoKinetix (OTC: PKTX) (www.protokinetix.com) is pleased to be able to report a comprehensive transplantation testing program being conducted for the last two years in conjunction with the University of Alberta transplant research team. The Company is collaborating with the James Shapiro Laboratory at the University of Alberta in Edmonton, Alberta. Dr. Shapiro directs the largest clinical islet transplantation program in the world.
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.16 (+0.22), NLSN: 45.57 (+0.53), VOYA: 44.81 (-0.14), NOC: 158.01 (+0.34), ARI: 17.41 (+0.12), OPHT: 52.02 (-0.56), WETF: 18.51 (-0.45), EVI: 4.28 (-0.01), MLNK: 3.57 (unch), DRRX: 2.35 (+0.01), RDUS: 46.23 (+1.12), AXDX: 23.08 (-0.05), HLX: 16.97 (+0.13), FANG: 78.93 (+1.73), FOXF: 16.48 (-0.20), SYK: 95.51 (+0.25), EHTH: 12.58 (-0.23)
ProtoKinetix Announces Settlement of Debt
Business Wire - Mon Mar 09, 9:23AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) today announced that it has retired its two largest debts to its largest creditor.
ProtoKinetix Inc. Announces Termination of Intrepid Agreement
Business Wire - Tue Oct 28, 9:23AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix"
announces that it has terminated and revoked its agreement for the sale of exclusive rights to the AAGP(TM) Blood Preservative Applications (the "Agreement" to Intrepid Innovations Corporation ("Intrepid". The Company delivered a notice of termination and revocation to Intrepid on October 27, 2014, with revocation effective as of October 10, 2014, due to the failure by Intrepid to fulfill its payment obligations to ProtoKinetix under the Agreement. ProtoKinetix Inc. Personnel Changes
Business Wire - Thu Oct 02, 9:54AM CDT
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce that it has appointed Ms. Susan Woodward, as the Company's Chief Financial Officer. Ms. Woodward has over twenty-five years' experience in the accounting and management fields. She has held various positions throughout her career in a variety of industries including health care, the oil and gas industry and public accounting. Her experience includes cash and grant management, budget and financial preparation, data analysis, federal and state reporting, policy and procedure setting and oversight of all accounting functions.
ProtoKinetix Welcomes Clarence E. Smith to its Board of Directors
Business Wire - Fri Jun 20, 6:00AM CDT
ProtoKinetix (OTCBB
KTX) (www.protokinetix.com) is pleased to announce the addition of entrepreneur and venture capitalist, Clarence E. Smith, to its Board of Directors. Mr. Smith brings much required, substantial financial and business experience with him as an addition to the Company's scientific accomplishments. 
